CJC-1295 DAC Dosage: How Much to Take, When & How

CJC-1295 DAC Dosage: How Much to Take, When & How

Disclaimer: This guide is for educational purposes only and does not constitute medical advice. CJC-1295 DAC is a research compound not approved by the FDA or most regulatory agencies for human use. Consult a qualified healthcare provider before considering use. The information presented reflects available dosing protocols used in research and performance contexts, but safety and efficacy in humans remain incompletely characterized.

Overview

CJC-1295 DAC is a synthetic growth hormone-releasing hormone (GHRH) analogue modified with a Drug Affinity Complex (DAC) that extends its half-life to 6-8 days, enabling once-weekly dosing schedules. Unlike native GHRH, which circulates for minutes, the DAC modification allows covalent binding to serum albumin, creating a depot effect that maintains steady stimulation of growth hormone (GH) release from the anterior pituitary.

The compound is administered via subcutaneous injection and is used primarily for GH axis stimulation in anti-aging, body composition, and recovery protocols. Understanding proper dosing, administration technique, and cycling principles is essential for optimizing outcomes and minimizing side effects.

Standard Dosing Protocol

Baseline Effective Dose Range

The standard dosing range for CJC-1295 DAC is 1,000–2,000 micrograms (1–2 mg) administered once weekly via subcutaneous injection.

• Lower end (1,000 mcg/week): Suitable for initial assessment, sensitivity testing, and maintenance protocols in lighter individuals or those prioritizing conservative dosing.
• Upper end (2,000 mcg/week): Common in aggressive anti-aging and body composition protocols; typically used by individuals with higher body weight or those seeking maximal GH stimulation.
• Most common protocol: 1,500 mcg (1.5 mg) once weekly strikes a balance between efficacy and side effect management for most users.

Frequency and Timing

CJC-1295 DAC is administered once per week due to its extended half-life. The long serum residence time (6-8 days) eliminates the need for multiple injections; multiple weekly doses do not align with the compound's pharmacokinetics and offer no known advantage.

Optimal injection timing:

• Pick a consistent day of the week (e.g., every Monday morning).
• Inject at the same time each week to maintain stable GH pulses.
• Early morning or evening injections are common; time of day is less critical than consistency.
• Allow at least 7 days between injections to prevent accumulation and dysregulation.

Dosing by Goal

Dosing strategy should align with intended outcome. While the overall 1–2 mg range remains constant, positioning within that range and cycling approach varies by goal.

Goal 1: Anti-Aging & Longevity

Typical dose: 1,000–1,500 mcg/week

Anti-aging protocols prioritize sustained, moderate GH elevation without extreme side effects. Lower doses reduce water retention and fatigue while still promoting tissue repair, collagen synthesis, and metabolic optimization.

• Start at 1,000 mcg/week for 4 weeks to assess tolerance.
• If well-tolerated, increase to 1,500 mcg/week.
• Maintain at this dose long-term with periodic breaks (e.g., 4 weeks on, 1 week off every 8 weeks).
• Cost estimate: $30–$60 per month at standard pricing.

Goal 2: Body Composition & Muscle Development

Typical dose: 1,500–2,000 mcg/week

Body composition protocols use higher doses to maximize anabolic signaling and lipolytic (fat-burning) effects. GH-mediated IGF-1 elevation supports protein synthesis and promotes preferential fat loss.

• Begin at 1,500 mcg/week for 2–4 weeks to establish baseline tolerance.
• Advance to 2,000 mcg/week if side effects remain manageable.
• Combine with resistance training and adequate protein intake to maximize anabolic response.
• Cycle pattern: 8–12 weeks on, 2–4 weeks off, then repeat.
• Cost estimate: $60–$90 per month.

Goal 3: Recovery & Performance Enhancement

Typical dose: 1,200–1,500 mcg/week

Recovery protocols emphasize tissue healing, collagen remodeling, and joint integrity. Moderate dosing balances recovery benefits with tolerability, particularly important for active athletes.

• Standard starting dose: 1,200 mcg/week.
• Adjust upward only if recovery metrics improve and side effects are minimal.
• Pair with adequate sleep, nutrition, and deload weeks to amplify recovery signaling.
• Cycle: 10 weeks on, 3 weeks off.
• Cost estimate: $45–$75 per month.

How to Administer

Administration Route

CJC-1295 DAC is administered exclusively via subcutaneous injection (under the skin, not intramuscular).

Injection Sites

Rotate between subcutaneous injection sites to minimize tissue irritation:

• Abdomen: Lower abdomen, pinch a fold of skin, inject into the fold (preferred for most users due to accessibility and reduced nerve density).
• Thighs: Outer thigh, 3–4 inches above knee.
• Upper arm: Back of upper arm between shoulder and elbow.
• Glutes: Upper outer quadrant (less common for subcutaneous injection).

Rotation schedule: Use a different site for each weekly injection to prevent lipohypertrophy (localized fat deposition) or lipoatrophy (localized fat loss).

Preparation & Injection Technique

1. Reconstitution (if powder): Mix with bacteriostatic water (typically 2 mL per vial); allow 30 minutes for dissolution. Gently roll vial; do not shake vigorously.
2. Cleanse site: Wipe injection site with an alcohol swab; allow to dry for 10–15 seconds.
3. Draw dose: Use a sterile syringe and needle (25–27 gauge, 0.5–0.625 inch length recommended for subcutaneous injection).
4. Pinch & inject: Pinch the skin to create a fold; insert needle at 45–90 degree angle into the fold. Inject slowly over 5–10 seconds.
5. Withdraw: Remove needle steadily; apply light pressure with alcohol swab or gauze for a few seconds.
6. Storage: Keep reconstituted CJC-1295 DAC refrigerated (2–8°C) if not used immediately; most providers recommend use within 30 days of reconstitution.

Needle & Syringe Selection

• Needle gauge: 25–27 gauge (thinner needles reduce injection site pain and tissue trauma).
• Needle length: 0.5 to 0.625 inches (adequate for subcutaneous depth without reaching muscle).
• Syringe volume: 1 mL insulin syringe (marked in units) for precise dosing of small volumes; standard 3 mL syringes are also acceptable.

Cycling & Timing Protocols

Standard On/Off Cycles

Despite CJC-1295 DAC's extended half-life, cycling (periodic breaks) is recommended to prevent receptor downregulation and maintain long-term responsiveness.

Recommended cycling patterns:

Pattern A (Conservative): 8 weeks on, 4 weeks off

• Best for anti-aging and maintenance.
• Minimizes cumulative side effects; allows pituitary recovery.

Pattern B (Moderate): 10–12 weeks on, 2–3 weeks off

• Optimal for body composition and muscle goals.
• Allows sufficient time for anabolic adaptation without excessive downtime.

Pattern C (Extended): 12–16 weeks on, 4 weeks off

• Aggressive protocol for performance athletes.
• Requires robust tolerance and monitoring; not recommended for beginners.

Load-In Phase

Some protocols include a "load-in" period during the first 1–2 weeks:

• Week 1: Inject 1,000 mcg on day 1 and day 4 (two injections, 3 days apart).
• Week 2 onward: Resume standard once-weekly dosing.

The rationale is to establish baseline GH elevation more rapidly. However, this approach increases early side effects and is optional; standard once-weekly dosing from the start also works effectively.

Washout Period

After completing an on-cycle, allow 2–4 weeks off before restarting. This permits:

• GHRH receptor sensitivity recovery.
• Clearance of accumulated peptide and metabolites.
• Assessment of baseline GH and IGF-1 without compound influence.
• Recovery from any accumulated side effects (water retention, fatigue).

Beginner vs Advanced Dosing

Beginner Protocol

Recommended approach:

• Start with 1,000 mcg (1 mg) once weekly.
• Duration: 4–6 weeks.
• Cycle: 8 weeks on, 4 weeks off.
• Rationale: Conservative dosing minimizes side effects while allowing assessment of individual tolerance and sensitivity.

Progression:

• If well-tolerated after 4 weeks and goals require higher doses, increase to 1,500 mcg/week.
• Do not exceed 1,500 mcg/week until at least one complete cycle has been completed.

Expected timeline to first effects: 3–4 weeks; peak adaptation typically occurs at 8–10 weeks.

Intermediate Protocol

Recommended approach:

• Begin at 1,500 mcg (1.5 mg) once weekly.
• Duration: 10–12 weeks.
• Cycle: 10 weeks on, 3 weeks off.
• Rationale: Moderate dosing provides solid anabolic/anti-aging stimulus with manageable side effect profile for users with prior peptide experience.

Dose adjustment:

• If side effects are minimal and goals support higher dosing, advance to 2,000 mcg/week after the first 4 weeks.
• Maintain 2,000 mcg/week for the remaining 6–8 weeks of the cycle.

Advanced Protocol

Recommended approach:

• Start at 1,500 mcg/week; escalate to 2,000 mcg/week by week 2–3.
• Duration: 12–16 weeks.
• Cycle: 12–16 weeks on, 4 weeks off.
• Rationale: Maximal dosing for athletes and aggressive body composition goals; requires robust tolerance and extensive side effect monitoring.

Requirements for advanced dosing:

• Prior experience with GH, CJC-1295, or other GHRH analogues.
• Baseline IGF-1, glucose tolerance, and metabolic markers assessed before starting.
• Quarterly monitoring throughout the cycle.
• Strong commitment to training, nutrition, and sleep optimization.

Common Dosing Mistakes

Mistake 1: Injecting More Than Once Per Week

CJC-1295 DAC's 6–8 day half-life means more frequent injections create excessive accumulation and dysregulated GH secretion. Once-weekly injection is optimal; twice-weekly dosing increases side effects without proportional benefit.

Mistake 2: Increasing Dose Without an Adequate Initial Trial

Many users escalate to 2,000 mcg within 1–2 weeks. This approach prevents proper tolerance assessment and amplifies early side effects (fatigue, water retention, headache). Start conservatively; increase only after 4+ weeks at baseline dose.

Mistake 3: Continuous Use Without Cycling

Running CJC-1295 DAC indefinitely without breaks causes GHRH receptor downregulation, diminishing responsiveness. Incorporate 2–4 week breaks every 8–12 weeks to maintain sensitivity.

Mistake 4: Inconsistent Injection Timing

Injecting at different times each week creates variable GH pulsatility. Pick a specific day and time; consistency maximizes steady-state GH elevation.

Mistake 5: Improper Site Rotation

Injecting repeatedly in the same location causes injection site reactions, lipohypertrophy, or abscess risk. Rotate sites systematically (e.g., abdomen week 1, thigh week 2, arm week 3, etc.).

Mistake 6: Ignoring Baseline Metabolic Assessment

Starting CJC-1295 DAC without baseline IGF-1, fasting glucose, and glucose tolerance testing prevents meaningful safety monitoring. These markers should be assessed before the first injection and re-evaluated every 8–12 weeks.

Mistake 7: Combining With Exogenous GH or Other GHRH Agonists

Stacking CJC-1295 DAC with exogenous growth hormone, GHRP (growth hormone-releasing peptide), or other GHRH agonists creates excessive GH elevation, increasing carpal tunnel risk, glucose dysregulation, and joint stress. Use CJC-1295 DAC monotherapy unless under direct medical supervision.

Dosing Summary Table

Final Considerations

CJC-1295 DAC dosing success depends on alignment with individual goals, tolerance, and systematic monitoring. The 1,000–2,000 mcg once-weekly range accommodates diverse objectives, from conservative anti-aging to aggressive body composition protocols.

Key principles for optimal dosing:

1. Start low; increase slowly.
2. Maintain consistent injection timing and site rotation.
3. Cycle regularly (8–16 weeks on, 2–4 weeks off).
4. Assess baseline metabolic health before use.
5. Monitor side effects and adjust dose accordingly.
6. Avoid stacking with other GH secretagogues.

Success with CJC-1295 DAC reflects not just dosage, but disciplined training, nutrition, sleep, and recovery practices. Dosing is one component of a comprehensive protocol; optimization across all factors maximizes outcomes and minimizes risk.